Aerie Pharmaceuticals

Aerie Pharmaceuticals is a biotechnology company that engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced successful interim 90-day topline data from its six-month Phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda® to Ganfort®. Roclanda® is marketed in the United S

Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

Why Is Aerie (AERI) Down 3.6% Since Last Earnings Report?

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q2 2020 Results - Earnings Call Transcript

Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.

Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020

Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Aerie Pharmaceuticals (AERI) Report Negative Q2 Earnings? What You Should Know

Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion

Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?

Is Aerie Pharmaceuticals a Buy?

Aerie has 2 marketed products and decent pipeline after a recent acquisition.

Aerie Looks Modestly Undervalued Despite High Cash Burn

Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue?

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q1 2020 Results - Earnings Call Transcript

Aerie (AERI) delivered earnings and revenue surprises of -12.00% and -3.32%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates

Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy?

Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.

Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak

Axsome Therapeutics

Biogen

bluebird bio

Puma Biotechnology

Pfizer

Rigel Pharmaceuticals

Success in clinical trials doesn't guarantee success on the market.

So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature

Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report?

The eye-care company reported better-than-expected fourth-quarter 2019 product revenue.

Here's Why Aerie Pharmaceuticals Jumped as Much as 14.4% Today

Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.

Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q4 2019 Results - Earnings Call Transcript

European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.

Aerie's (AERI) Application for Roclanda Accepted in Europe

Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue?

Akebia Therapeutics

Cytokinetics

Novavax

Telesis Bio Inc

For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.

5 “Strong Buy” Biotech Stocks With More Than 80% Upside

Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.

News for Aerie Pharmaceuticals Stock (AERI)